ࡱ > #` C bjbjmm ݗ 2 F D D D " " " # |$ \ 4 $ ( % F R% R% t% O& & < ' H4 J4 J4 J4 J4 J4 J4 $ c6 h 8 d n4 - D ) O& O& ) ) n4 p P R% " t% 4 / / / ) J D t% D t% / / ) H4 / / D D / t% $ @-P3 " ^+ $ / / 4 0 4 / /9 , > /9 / /9 D / =' L ' 6 / ' , ' ) =' =' =' n4 n4 . ^ =' =' =' 4 ) ) ) ) D D D D
NSTEMI: INITIAL MANAGEMENT ORDER TEMPLATE
(Referenced Version)
This template lists elements, drugs, doses, and strategies that should be highly considered when creating admission order sets based upon recent clinical practice guidelines, medication package inserts, and emerging evidence.
DEMOGRAPHICS
Age ___________ years Weight __________ kg
DIET ORDERS
( NPO
( 2 gm sodium restricted/low cholesterol/low fat
( Diabetic _________________ calorie ADA
( Other (specify) _______________________
ACTIVITY ORDERS
( Bed rest
NURSING ADDIN EN.CITE Anderson20073317Anderson, J. L.Adams, C. D.Antman, E. M.Bridges, C. R.Califf, R. M.Casey, D. E., Jr.Chavey, W. E., 2ndFesmire, F. M.Hochman, J. S.Levin, T. N.Lincoff, A. M.Peterson, E. D.Theroux, P.Wenger, N. K.Wright, R. S.Smith, S. C., Jr.Jacobs, A. K.Adams, C. D.Anderson, J. L.Antman, E. M.Halperin, J. L.Hunt, S. A.Krumholz, H. M.Kushner, F. G.Lytle, B. W.Nishimura, R.Ornato, J. P.Page, R. L.Riegel, B.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll CardiolJ Am Coll Cardiole1-e157507Angina, Unstable/*diagnosis/etiology/*therapyBiological Markers/bloodCardiology Service, HospitalCardiovascular AgentsHumansMyocardial Infarction/*diagnosis/etiology/*therapyMyocardial RevascularizationRisk AssessmentSyndrome2007Aug 1417692738http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17692738 1(pg e35)
( Continuous ECG monitoring
( Supplemental O2 to keep arterial saturation > 90%
( Nitroglycerin Protocol: PRN use of 0.4mg q5 min for chest pain
MEDICATION ALLERGIES
( Specify: ________________________________________ Reaction (if known): __________________________
DIAGNOSTIC STUDIES ( 12-lead ECG NOW ( 12-lead ECG FOR RECURRENT CHEST PAIN
( 12-lead ECG IN AM (____/___/___ ___:___ AM)
LABORATORY STUDIES
CARDIAC MARKERS
( Troponin T/ Troponin I: NOW AND EVERY ________ hours X ________ times
OR
( CK AND CK-MB: NOW AND EVERY ________ hours X ________ times ROUTINE LABS
Chemistry panel: ( NOW ( DAILY IN AM
CBC: ( NOW ( DAILY IN AM
Fasting lipid panel: ( IN AM
HbA1c: ( IN AM
Calculate creatinine clearance (CrCl): _______ml/min
CrCl ml/min = (140- age) X weight (kg)/(serum creatinine X 72) multiply by 0.85 if female
MEDICATIONS FOR ALL PATIENTS
( Aspirin: Loading dose (NOW) 162 mg to 325 mg chewed orally, then maintenance dose (DAILY) of 81 mg to 162 mg orally (or 162 mg to 325 mg DAILY after stent implantation). (If aspirin intolerant, give clopidogrel) ADDIN EN.CITE Anderson20073317Anderson, J. L.Adams, C. D.Antman, E. M.Bridges, C. R.Califf, R. M.Casey, D. E., Jr.Chavey, W. E., 2ndFesmire, F. M.Hochman, J. S.Levin, T. N.Lincoff, A. M.Peterson, E. D.Theroux, P.Wenger, N. K.Wright, R. S.Smith, S. C., Jr.Jacobs, A. K.Adams, C. D.Anderson, J. L.Antman, E. M.Halperin, J. L.Hunt, S. A.Krumholz, H. M.Kushner, F. G.Lytle, B. W.Nishimura, R.Ornato, J. P.Page, R. L.Riegel, B.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll CardiolJ Am Coll Cardiole1-e157507Angina, Unstable/*diagnosis/etiology/*therapyBiological Markers/bloodCardiology Service, HospitalCardiovascular AgentsHumansMyocardial Infarction/*diagnosis/etiology/*therapyMyocardial RevascularizationRisk AssessmentSyndrome2007Aug 1417692738http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17692738 1
Loading dose: _________________________ ___________ mg orally.
Daily dose: _____________________ ___________ mg orally.
( Clopidogrel: Loading dose 300 -600 mg orally, then daily dose of 75 mg orally
(for patients who are aspirin intolerant, or in addition to aspirin in initial conservative strategy or as option with either clopidogrel or IV GP IIb/IIIa inhibitors prior to Cath)
Loading dose: _________________________ ___________ mg orally.
Daily dose: _____________________ ___________ mg orally
( Statin: Drug: ______________________ _________ mg daily (regardless of LDL)
( ACE/ARB: (if LVEF<40%, CHF on exam, or pulmonary edema if SBP >100 mmHg)
Drug: _________________________ ___________ mg _____________ times day
BETA BLOCKERS (Hold if signs of heart failure, evidence of low-output state, high risk for cardiogenic shock* or contraindications to beta blocker therapy**)
( Oral Beta-blocker:
Drug: ____________________ _______ mg _____ times day
( IV Beta-Blockers (Optional; recommended if persistent ischemic symptoms, hypertension, or tachycardia and no signs of hemodynamic instability) Drug: ___________________ _____ mg IV for ____ doses every ___ minutes
*Risk factors for shock (greater number of risk factors, the greater the risk): age > 70 years, SBP < 120 mmHg, sinus tachycardia with HR > 110 bpm or < 60 mmHg, or increased time since onset of symptoms.
**Contraindications for beta-blockers: PR interval > 0.24 sec, second or third degree AV block, active asthma, or reactive airway disease.
( Stop NSAIDS (except aspirin)
( GI Prophylaxis (with history of GI bleeding)
Drug: _________________________ ___________ mg _____________ times day
RISK STRATIFICATION
( High risk: Refractory angina, hemodynamic or electrical instability, elevated cardiac markers (TnT, TnI), new or presumably new ST segment depression, signs or symptoms of HF or new or worsening mitral regurgitation, high risk from noninvasive testing, reduced EF <40%, High risk score (eg. TIMI or GRACE) or PCI within 6 months or prior CABG.
( PREFER INITIAL INVASIVE STRATEGY (Diagnostic Angiography with intent to revascularize)
( Low risk: Low risk score (eg. TIMI or GRACE) and absence of above high risk features
( PREFER INITIAL CONSERVATIVE STRATEGY (especially if female or based on patient preference)
INITIAL INVASIVE STRATEGY (Higher Risk)
ANTICOAGULANT THERAPY (Choose one):
( Unfractionated heparinA (continue for 48 hrs)
Bolus: 60 U/kg IV, not to exceed 4000 U
Infusion: 12 U/kg/hr IV, not to exceed 1000 U/hr, to achieve goal PTT 1.5 to 2.0 times local reference standard; check PTT in 6 hours and adjust heparin as indicated
OR
( EnoxaparinA 1 mg/kg subcutaneous every 12 hours (if CrCl < 30 mL/min, give 1mg/kg every 24 hours)
OR
( BivalirudinB Bolus: 0.1 mg/kg IV
Infusion: 0.25 mg/kg/hr IV (Use with caution if CrCl < 30 mL/min)
OR
( FondaparinuxB 2.5 mg subcutaneously once daily (Avoid if CrCl< 30 mL/min)
*Continue for the shorter of the duration of hospitalization, 8 days, or until determined by management during PCI.
ALevel of evidence A with data from multiple trials.
BLevel of evidence B with data from a single trial.
( Schedule for catheterization and revascularization if appropriate
GLYCOPROTEIN IIB/IIIA THERAPY (Choose one or use clopidogrel as above)
( Abciximab (if no delay to cath)
Loading: 0.25 mcg/kg IV bolus
Infusion 0.125 mcg/kg/min IV (Reserve for patients with planned PCI within 12 hours)
OR
( Eptifibatide Loading: 180 mcg/kg IV bolus
Infusion: 2.0 mcg/kg/min (Reduce to 1.0 mcg/kg/min if CrCl < 50mL/min)
OR
( Tirofiban Loading: 0.4 mcg/kg/min for 30 min (R e d u c e t o 0 . 2 m c g / k g / m i n f o r C r C l d" 3 0 m L / m i n )
I n f u s i o n : 0 . 1 m c g / k g / m i n ( R e d u c e t o 0 . 0 5 m c g / k g / m i n i f C r C l d" 3 0 m L / m i n )
* C a n b e s t a r t e d p r i o r t o o r i n c a r d i a c c a t h e t e r i z a t i o n l a b .
I N I T I A L C O N S E R V A T I V E S T R A T E G Y ( L o w e r R i s k )
A N T I C O A G U L A N T T H E R A P Y ( C h o o se one):
( Unfractionated heparinA (for 48 hours)
Bolus: 60 U/kg IV (not to exceed 4000 U)
Infusion: 12 U/kg/hr IV (not to exceed 1000U/hr) to goal PTT 1.5 to 2.0 times local reference standard; check PTT in 6 hours and adjust heparin as indicated.
OR
( EnoxaparinA 1 mg/kg subcutaneous every 12 hours (if CrCl < 30mL/min, give 1 mg/kg every 24 hours)
OR
( FondaparinuxB 2.5 mg subcutaneously once daily (avoid if CrCl<30mL/min; Preferred if high risk of bleeding)
*Continue for the shorter of the duration of hospitalization, 8 days, or until PCI.
ALevel of evidence A with data from multiple trials.
BLevel of evidence B with data from a single trial.
( Schedule assessment of LVEF
( Schedule for stress test
( Revert to invasive protocol if recurrent symptoms/ischemia, or develops high risk features such as heart failure, arrhythmias, or positive cardiac biomarkers.
Copyright 2007 by the American College of Cardiology. This content is owned by the ACC. A person accessing it may print the material and use it for his or her personal, institutional, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted, or reproduced in any medium, whether now known or later invented, except as authorized in writing by the ACC. This material is intended for reference and does not represent ACC policy. This content is not endorsed by the ACC.Copyright 2007 by the American College of Cardiology. This content is owned by the ACC. A person accessing it may print the material and use it for his or her personal, institutional, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted, or reproduced in any medium, whether now known or later invented, except as authorized in writing by the ACC. This material is intended for reference and does not represent ACC policy. This content is not endorsed by the ACC.
PAGE
PAGE 1
Page PAGE 1 of NUMPAGES 4
Copyright 2008 by the American College of Cardiology. This content is owned by the ACC. A person accessing it may print the material and use it for his or her personal, institutional, non-commercial reference. Other terms and conditions for use may apply, particularly for commercial purposes. For more details, please contact the ACC in writing. This material is intended for reference and does not represent ACC policy. This content is not endorsed by the ACC. If any modifications are made to the content or layout of this material, all representation of the material as derived fromACC or NCDRshould be removed.
Endnote:Bottom of Form ADDIN
ADDIN EN.REFLIST 1 Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p45
Anderson et al, 2007, p 92.
Anderson et al, 2007, p 35.
Anderson et al, 2007, p 35
Anderson et al, 2007, p 36
Anderson et al, 2007, p 34.
Anderson et al, 2007, p 34.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 37
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 38.
Anderson et al, 2007, p 38.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 37.
Anderson et al, 2007, p 37.
/ C D I Q % & ̽zcOcO8 ,hgtQ hw& 6B*CJ OJ QJ ^J aJ ph &hgtQ 6B*CJ OJ QJ ^J aJ ph ,hF hgtQ 6B*CJ OJ QJ ^J aJ ph 2htJ hw& 56B*CJ OJ QJ \^J aJ ph ,htJ hw& 6B*CJ OJ QJ ^J aJ ph #h`5 hw& 5CJ OJ QJ ^J aJ h=P 5CJ OJ QJ ^J aJ ,h`5 hw& 5B*
CJ OJ QJ ^J aJ ph &hw& 5B*
CJ OJ QJ ^J aJ ph j hw& U
/ D & 3 ^ j k q
K
P x gdw& x gdw& gdw& hx ^h`gdw&
-D M
gdw& 7$ 8$ H$ gdw& $a$gdw& gdw& ; ; C & 2 3 ^ j k l m q r s
ճĢĢijijբăm\mJ #h$ h$ CJ H*OJ QJ ^J aJ h$ h$ CJ OJ QJ ^J aJ +j h$ CJ OJ QJ U^J aJ mHsH h$ hw& CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ h`5 hw& CJ OJ QJ ^J aJ h`5 hw& CJ OJ QJ ^J aJ 1h`5 hw& CJ OJ QJ ^J aJ fH q
K |k|ZI;;I hw& CJ OJ QJ ^J aJ h`5 hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ h$ hw& CJ OJ QJ ^J aJ h$ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h$ hw& CJ OJ QJ ^J aJ #h3h h3h CJ H*OJ QJ ^J aJ #h3h hN CJ H*OJ QJ ^J aJ +h3h h3h CJ H*OJ QJ ^J aJ mHsH+j h$ CJ OJ QJ U^J aJ mHsH K ` C D W g + H f y z
bx gdw&
bx gdw&
Fbx gdw&
x gdw& gdw& x gdw&
x gdw&
x gdw&
-D M
gdw& K ` a b % C D W g h j ͼͼͼ}ͼlX &htJ hw& 5>*CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ #h`5 hw& 5CJ OJ QJ ^J aJ hw hw& CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ h`5 hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h`5 hw& CJ OJ QJ ^J aJ j + 0 1 3 6 9 : < G H \ ] ^ ` f l p q ﺩޕqqqީީ #h[ hw& 5CJ OJ QJ ^J aJ #htJ hw& >*CJ OJ QJ ^J aJ &htJ hw& 5>*CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ #htJ hw& 5CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ ,q s x z & ' ( / 1 2 @ C V ] | ݼݫݫݫwcݼݫݫݫR h$ h$ CJ OJ QJ ^J aJ &htJ hw& 5>*CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ #htJ hw& 6CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ hw& 5CJ OJ QJ ^J aJ #h[ hw& 5CJ OJ QJ ^J aJ #htJ hw& 5CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ z & # # $ $ k$ "% e% % % % % D& & [x ^[`gdw& gdw&
[x ^[gdw& T^Tgdw& T^T`gdw& `gdw& x ^`gdw& Tx ^T`gdw&
-D M
gdw&
bx gdw& # # # # # # # # # # # $ $ $ $ $ $ %$ '$ ($ 9$ >$ N$ S$ h$ i$ |k|WI hn CJ OJ QJ ^J aJ &htJ hw& 5>*CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ hw& 5CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ #htJ hw& 5CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ #h$ h$ CJ H*OJ QJ ^J aJ h$ CJ OJ QJ ^J aJ #j h$ CJ OJ QJ U^J aJ i$ j$ k$ % % !% "% /% ]% d% e% j% p% % % % % % % ȶ}o`}oO>O j hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ hw& 5CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ #htJ hw& 5CJ OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ *j hn 0J 6CJ OJ QJ U^J aJ #hN hw& 6CJ OJ QJ ^J aJ #htJ hw& 6CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ 'j hn 0J CJ OJ QJ U^J aJ % % % % % % % % % % % % % & & & B& ɸp_N=N츪+ #htJ hw& 6CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ *j hn 0J 6CJ OJ QJ U^J aJ #hN hw& 6CJ OJ QJ ^J aJ #hc& hw& 6CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ #hc& hw& 5CJ OJ QJ ^J aJ hw& 5>*CJ OJ QJ ^J aJ &htJ hw& 5>*CJ OJ QJ ^J aJ B& C& D& & & & & ' +' .' /' 0' 1' 2' C' ȷr^M?+ &h^ hw& 5>*CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ 'j h
` 0J CJ OJ QJ U^J aJ hw& CJ OJ QJ ^J aJ hxt hw& CJ OJ QJ ^J aJ #hxt hw& 5CJ OJ QJ ^J aJ &hxt hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ *j hn 0J 6CJ OJ QJ U^J aJ & & 0' G' ' ' _( `( -) ) ) * Q* e* + , , `gdw& x ^`gdw&
-D M
gdw&
x `gdw& x gdw&
-D M
& gd
` x -D M
& gdw&
-D M
& gdw& gdw& C' D' F' G' V' v' ' ' ' ' ' ' ' ' ( ( ( ν~jYE4 h^ h
` CJ OJ QJ ^J aJ 'j h#4 0J CJ OJ QJ U^J aJ hc hw& CJ OJ QJ ^J aJ &h^ hw& 5>*CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hS/ hw& >*CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ hxt hw& CJ OJ QJ ^J aJ hw& 5CJ OJ QJ ^J aJ #h^ hw& 5CJ OJ QJ ^J aJ hw& 5>*CJ OJ QJ ^J aJ ( -( _( `( ( ( ( ( ( ( ( ( a) b) ) ) ) ) ) ) ) ) ) ) * * ͻxgxgYxgK hw& CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ #h hw& 5CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ hw& 6CJ OJ QJ ^J aJ #hc hw& 6CJ OJ QJ ^J aJ hS/ hw& CJ OJ QJ ^J aJ hc hw& CJ OJ QJ ^J aJ h^ hw& CJ OJ QJ ^J aJ * P* Q* e* f* g* p* r* + + + + + , , , ͼxdP>/> hw& 5CJ OJ QJ ^J aJ #h hw& 5CJ OJ QJ ^J aJ & j h hw& CJ OJ QJ ^J aJ 'j h#4 0J CJ OJ QJ U^J aJ hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ &h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ h ^ hw& CJ OJ QJ ^J aJ htJ hw& CJ OJ QJ ^J aJ , , , , $, &, q, r, s, t, u, , , , , - - - 4- ˷p^O^>˷ h hw& CJ OJ QJ ^J aJ hw& 5CJ OJ QJ ^J aJ #h hw& 5CJ OJ QJ ^J aJ & j h hw& CJ OJ QJ ^J aJ 'j h#4 0J CJ OJ QJ U^J aJ hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ &h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #h[ hw& 5CJ OJ QJ ^J aJ , s, , , - L- u- . !. . . . . h x -D M
& ^`gdw&
-D M
& gdw& x x -D M
& ^`gdw& -D M
& ^`gd -D M
& ^`gdw& x -D M
& gdw&
-D M
gdw& x gdw& ^`gdw& 4- 5- 7- K- L- M- R- v- ~- . . . . !. ". #. -. ʹ٧٧ٓr`O>*&h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ h 5CJ OJ QJ ^J aJ #hQw h 5CJ OJ QJ ^J aJ 'j h 0J CJ OJ QJ U^J aJ #h hw& >*CJ OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ hN 6CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ )h hw& 56CJ H*OJ QJ ^J aJ -. .. /. 0. T. . . . . . . . . . ٹkS:% (h$ hw& CJ OJ QJ ^J aJ mH sH 1h$ hw& 56CJ H*OJ QJ ^J aJ mH sH .h$ hw& 5>*CJ OJ QJ ^J aJ mH sH (h$ hw& CJ OJ QJ ^J aJ mH sH j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ *j h 0J 6CJ OJ QJ U^J aJ #h hw& 6CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ )h hw& 56CJ H*OJ QJ ^J aJ
. . . . . . . . . . . . / ±weTC/ &h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ #h h 6CJ OJ QJ ^J aJ *j h 0J 6CJ OJ QJ U^J aJ #h hw& 6CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ #h hw& >*CJ OJ QJ ^J aJ (h$ hw& CJ OJ QJ ^J aJ mH sH +h$ hw& >*CJ OJ QJ ^J aJ mH sH . . G/ H/ / / &0 j0 k0 0 0 0 M1 P1 x -D M
gdw&
-D M
gdw&
x -D M
gdw&
-D M
gdw& gdw& x gdw&
-D M
& gdw& x -D M
& ^`gdw& x -D M
& gdw&
/ / */ 9/ :/ D/ E/ F/ G/ H/ / / / / / / / &0 '0 (0 j0 ǸǢǸǸkYkYH: hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #h+9 hw& 6CJ OJ QJ ^J aJ )h+9 hw& 56CJ H*OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ hN h CJ OJ QJ ^J aJ *j h 0J 6CJ OJ QJ U^J aJ hw& 6CJ OJ QJ ^J aJ #h hw& 6CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ )h hw& 56CJ H*OJ QJ ^J aJ j0 k0 0 0 0 0 0 0 0 0 0 0 0 0 0 ƴأ~l[I[8& #h hw& >*CJ OJ QJ ^J aJ hE hw& CJ OJ QJ ^J aJ #h hw& 6CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ #h^ hw& 5CJ OJ QJ ^J aJ &h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #h hw& 6CJ OJ QJ ^J aJ #h hw& 5CJ OJ QJ ^J aJ &h hw& 5>*CJ OJ QJ ^J aJ &h[ hw& 5>*CJ OJ QJ ^J aJ 0 0 0 0 1 I1 J1 K1 L1 M1 P1 Q1 R1 ^1 a1 b1 i1 ~1 秊raM? hw& CJ OJ QJ ^J aJ &h hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ h h CJ OJ QJ ^J aJ 'j h 0J CJ OJ QJ U^J aJ #h hw& 6CJ OJ QJ ^J aJ #h hw& >*CJ OJ QJ ^J aJ hE hw& CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ P1 1 1 1 ^2 2 2 p3 r3 3 3 4 24 \4 4 -D M
& ^`gdw& x -D M
& gdw& 7$ 8$ H$ gdw&
-D M
gdw&
-D M
gdw&
-D M
gdw& -D M
^`gdw& x -D M
^`gdw& ~1 1 1 1 1 1 1 1 1 1 1 1 1 1 ̻raL4 .hX hw& 5>*CJ OJ QJ ^J aJ mHsH (h[ hw& CJ OJ QJ ^J aJ mHsH j hw& CJ OJ QJ ^J aJ #hw& hw& 5CJ OJ QJ ^J aJ hw& h CJ OJ QJ ^J aJ 'j h 0J CJ OJ QJ U^J aJ #hw& hw& 6CJ OJ QJ ^J aJ hw& hw& CJ OJ QJ ^J aJ #hw& hw& >*CJ OJ QJ ^J aJ h hw& CJ OJ QJ ^J aJ hN hw& CJ OJ QJ ^J aJ
1 1 1 1 1 \2 ^2 `2 p2 2 2 2 2 2 2 뭘ucM*CJ OJ QJ ^J aJ (hN hw& CJ OJ QJ ^J aJ mHsH +hX hw& 6CJ OJ QJ ^J aJ mHsH+hX hw& >*CJ OJ QJ ^J aJ mHsH"hw& CJ OJ QJ ^J aJ mHsH (hX hw& CJ OJ QJ ^J aJ mHsH2 n3 p3 r3 3 3 3 3 4
4 4 !4 "4 ͳ|hWFh1 )h4 hw& 56CJ H*OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ &h4 hw& 5>*CJ OJ QJ ^J aJ hw& OJ QJ "hE hw& 56CJ OJ QJ aJ 8hE hw& 5B*CJ OJ QJ \fH ph q
2hw& 5B*CJ OJ QJ \fH ph q
(hE hw& 6OJ QJ fH q
hw& 6CJ OJ QJ aJ hE hw& 6CJ OJ QJ aJ "4 $4 14 24 34 84 ]4 e4 4 4 4 4 4 4 5 5 5 tcR> &h4 hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ 'j h 0J CJ OJ QJ U^J aJ h CJ OJ QJ ^J aJ #h4 hw& >*CJ OJ QJ ^J aJ h$ hw& CJ OJ QJ ^J aJ #h4 hw& 6CJ OJ QJ ^J aJ h4 hw& CJ OJ QJ ^J aJ 4 4 f5 i5 5 5 /6 e6 6 6 6 u7 ; ; ; ; ; ; ; ; gd}
$ a$ gd gG x ^`gdw& x gdw&
-D M
& gdw& x -D M
& ^`gdw& x -D M
& gdw& 5 5
5 5 25 c5 d5 e5 f5 i5 j5 k5 w5 x5 y5 z5 5 5 5 5 5 ٹn]Iٹ8 h4 h CJ OJ QJ ^J aJ &h4 hw& 5>*CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #hQw hw& 5CJ OJ QJ ^J aJ #h4 h 6CJ OJ QJ ^J aJ *j h 0J 6CJ OJ QJ U^J aJ #h4 hw& 6CJ OJ QJ ^J aJ hw& CJ OJ QJ ^J aJ h4 hw& CJ OJ QJ ^J aJ )h4 hw& 56CJ H*OJ QJ ^J aJ 5 5 .6 /6 06 e6 f6 6 6 6 6 6 6 6 6 6 6 u7 ; ; ; ; ; ; ; ; ; ; ; ; ɷɷvi_[WOKOKOKOK hs, j hs, UhgtQ h}
h
g CJ ^J aJ h gG h gG CJ ^J aJ hw& CJ OJ QJ ^J aJ h4 hw& CJ OJ QJ ^J aJ h[ hw& CJ OJ QJ ^J aJ j hw& CJ OJ QJ ^J aJ #h+9 hw& 6CJ OJ QJ ^J aJ )h+9 hw& 56CJ H*OJ QJ ^J aJ #h4 hw& 6CJ OJ QJ ^J aJ hw& 6CJ OJ QJ ^J aJ ; ; ; ; ; ; ; ; ; ; ; ; ; ; N> O> o> p> q> wA yA h^h`gd@t gdn $ a$ gdn gdO
!& h]hgd$c hh]h`hgd$c &`#$gd$c ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; < < = = N> O> W> ѾѾѾѾ뚋t` &hu h gG 5<CJ OJ QJ ^J aJ h gG <CJ ^J aJ hO CJ OJ QJ aJ hx; hO CJ OJ QJ aJ hs, h$c h gG CJ OJ QJ aJ !h{ CJ OJ QJ aJ mH nH u%j h$c h$c CJ OJ QJ UaJ h$c h$c CJ OJ QJ aJ h{ 0J mH nH uh gG
h gG 0J j h gG 0J U !W> e> f> m> n> o> p> q> r> > > > SA fA wA xA yA zA A A A A A A A A B B 1B 2B PB QB oB pB B B B B B B B B C
C Ʒoooooooooooooo )j h}
h gG 0J CJ OJ QJ UaJ h}
h gG 6CJ OJ QJ aJ hgtQ h gG CJ H*OJ QJ aJ %j h}
h gG CJ OJ QJ UaJ h}
h gG CJ OJ QJ aJ hu h gG 5CJ OJ QJ aJ ,j hu h gG 5CJ OJ QJ U^J aJ #hu h gG 5CJ OJ QJ ^J aJ +yA A A A A A A A A B B 0B 1B OB PB nB oB B B B B B B B B C C gd
gd
`
#
gdn C 'C (C FC GC eC fC C C C C C C gd}
gd
C (C )C GC HC fC gC C C C C C hgtQ hs, )j h}
h gG 0J CJ OJ QJ UaJ h}
h gG CJ OJ QJ aJ 3 ;0AP BP / =!"#$% @ 0 :pw& ;0AP BP / =!"#$% P 6 0 ;0AP BP / =!"#$% < 0 :pw& ;0AP BP / =!"#$% 6 0 ;0AP BP / =!"#$% 6 0 ;0AP BP / =!"#$% @ 0 :pw& ;0AP BP / =!"#$% P < 0 :pw& ;0AP BP / =!"#$% ] D d - xy >
C A b '] dRq @mB ] D i n \ dRq @mBPNG
IHDR H sRGB pHYs od \IDATx^ ]E
t@$MQ
Ȩ62 mle2cP`۱ndП<
Q 侯u93'(7SjժUkUU˖-i3666226::I::::6|dy_/y> -~{/گc# զO൛O[gu6bN{4Di+`r54 CUe+
T(PQ(F[U DvB? AcRP-^믯~ T&' (%-]2{]c߭Px4G/n&+J\E*
H֕GRjIЮ45d3-wNE B ⃟@gZJ7kfmM >{ʌ&甴HxE*
4@Lf ^uuIHP
A
$ztOX9Ip@Bpij&N]s{=y
ݯJT(PQ@
Q 1s;K}\ 4NOPAEǼQ%'!T% MZi ՍwsΖ|xlILX)CNE*
4@#]HWȭyϝy|٥iֳFtTK~[>6IR!-%3Ƶ]RSUY##[4k3ҚӠ*QQ@E-RuVw^rg_L{Izy
I+IDm%$D.'9]h7Y|yvLIQ(PQ@E(<!Mu=SAy<~PE
uwUۀ' @X}ƔN#N+\E*
@sD2r}ddERJaҙJ O}< *m3ĭT(PQFfʣfGSbT $ wSF] %W
*
))\[ɧ~vӜ(bOv_{ BXq$?l+
T("Pcg IaoMRCYZi 99ф*OR5[Q
KF T~iJ"K iWS=]{*ik ړX [2sձzG|MQ<,S͡ZMI/[Bvm. \Ջaa95LU*
`h<A.SsH|
:,k3m^8:G}ѭ|0X}*
T(PQ#h&R= D ^n/輄8o}ѻ[է@E:E ?9 7 ϣ946~Fj "_ё[ GRU*
c`@ u'=:}HņtXD|C{0Qµ@EAqeP|N%"
MIAKnAe[)§Cf%+GLUz=rP(|ǥ!?})啪X-l /*KVu
w˫GgG_L\^ NDvX˓6?glfQ$[tWϾ%mv#M㟂 2i4\=j&+$lWra9 c-&x |W{SZ4iKLjb_`NH4HI+y9)9,7/ /%s >+Ѐ,[qJvdw#%*ntr5d)RUK϶[HF8jNnP=5vn. Z XOnlSзVUH'{{? -sL~ww^N'}}?|mmPo? f
G;UJ-Ub;OcK,y衇D_W&~駞bmdZ{>r-yjQOM7:"eG6{tԽJ貗_FCokXPCUںZY#OdDm:5?zNiݭ˃ѩ$W]u⯱ίywe^(/@Cʙ C )?@կ~ ?>(}3C
)&x &:EP'|^\:u7hɓ' \sͭt+?Ҹ_QjX |r{שm ҃?O=IVX`]O9v.Hdweրv4ï;wndinԩ^xaqWl2$ SN)*[% / }ȵD ~n;qK7CKp)l}A¢Bb Ri8#Aͺ^I̙wdҵdUM
C
J*BI3k!
۟ \JbK_AD~~;.RCdQ\=a?57WhzmT@cg@_% }A.X^| g?[#n9ڎulR t.;bҔ(Sbm2
\= \ Vm0X[k5)`NV`&̍fp#/.E:eIQYdJ[8˷ 94H%NL#μ`ԠxU'fDҬ.儾f{mf y, XcZ z Td= ՕUI$+ W{y1ERvfV%;;ZH$4l%}EEs U5Q;a+ X>[$$S=I@D ?y|k4:
h y9ꨣlPVZWKO
'
#
&굅@_] 83XQU1Kp} fl ʹ,d $6:k]N7L$[)>YĦ2| hR[(MthGf淿m3 Cog-zoEj7EL"#+@7CX@3!td5*ѩҹPSTһo~E< R,
az[O#\_|Uf ̛ٳgGJ𤈣n2hȚ.fM*0ۏMQ#I}ZV"ގPk:Á8Xd8ȥW6k+ XY*H'|R_6h}BTH HguL~oW8 h"iC%Zo2Ј6R$֜@e{dDjtVAd-aeD%E
ۍDX#:Izy:{a^% '|2_#L?l#?`^)Bџ^< 6 .P%AWF_ώ\l
"W a<ʆr< (怟c&N鰕MK9HzLf)S,/O%#hl8VYQ dbKN>OX{& .Wo6ENuc @ ԀZl*$x8묳 cD6ȶ(tVGZ y$s |2$g.0b(X Xg}0|䊟pn0xpwن1+oۮ>Uuf遖Ȁ
w9G2$k 1ߒ PlX@Q>Zg)<M AnK!6/tCԓ8@XKdfE!/Y-Pnn o?eh]&pDc'>nL.5@y\qMk 2ab< #': /8`-a{^C,L}Jy9QIO>$ ϚwBB~vॡ?DWa6Z>FT$r
/<@,\4mSRZQ mkhL)V˃ )n{dCbNrfoteT4DI
B{0:FQh_WԡA6a5v$c U$-$ަ>ܢ_qQ+GT [E/N;.'KbMYO% _\1jd4P=0kJsUԑ9)jqK~MZ=QG\&\A
| +aL N5Â&T(p IL9:WV Pg!K7 D:XiJC9ğ(,DǑUwJ&r%F R1zaX X9e G1FP
&W6.ݶ+Z @v үs%l|r˩7oEbP@͡ I7,άT"
xрС>"lGvrdmHލ ق0^L5?F,p=Ca
r= Zd`&K␜ -vXj} ݉<=VA N'q)DUv l
w)h_a<9 aɱ2,0*.ZC":Xu CF+zف&+]$>:_$,J4jS&#$h%GWl_ގ A*S
"4] d+7dW!*![9 ;>wlܼ:"&gi
|iw ȅ$٪HTل胙 Ca/L ${/x=VNVmԐ7 GUy1 mi΄w<y6S6Ə қ(#Il=Z6& EZeoAh L=GG{U$5~\o 'B,R`L(_>h&z(vy/-7BNO8UTz1S) Sai/-08hyi%jӦ}Y#fC`K@:w4H 1c&e+h@$ޑB@ڌ^$ɪa QtvWR#z9%c5
b*=Y;L;d"]tO8LXmDj&$K|~BXpŸj:^}"sl(] .k&}@*O<ކxX^UX Ay$
w
hp K?h [z+u;FܻkR&_<+]>Q.yDv#]5Xzw
s!+:D(=vnрY7oe]&V~EbUPA`R{EߐV5 FXINpm,y%|'5 /]/ "~J&)lG*0ut ,~Ds}&[vF#j./|a=l1#(ǻƨ M|q ':9]@؛.!i&U) m=t+HD|0
6ayQbNHa% :֧f"w>U'[; 6 cnG&Fjþr8@dW12Wk=p'g=v5\aA?1ǜtIW.\2C# ȫUzF)w{,:jHx8
Ձovz ւdžǿeJ-K$e]yЎqo
*jꚫpgg?@ׯx_`⤳;L!MN9z#
W|O<zZ. 1F#B:䓷jqmG*M^ rYQ ,+,'j}! KGf0/``9XUɎP U |_CwBW#6h =Ix3mlAM6}?w˽kkw)C\9.Ş}jӠMdm͑$bc]vQDS}Ug}W ёҨ#i:[ً>8eJӡ]HlDw znqzDR! Hύ8h>v? si[ _أ&f'J ex7́5 .q8@ FIֶܳävzo]\O&f5aU Հ,
Z(Щ ܈9sD CR='ax1#7?KMV:\ \ |~)Yrj =ŧEX'yW-oEh;e-8=7hTq[D\rq p 3Kn <Wɔwzz?/y$q]a,w.M/JbBp'lwi{Ȧ h3yntܡ,G 5@q;[4 :F.4/OY*GaڈV ~wH7T}0.5WV pT7HF R5PWxiNOVaomнox߽o88{c<5wHDSJrh97aR;F__-d_zPUVX簋! 62Z뫺`{b CNh՛%BD$#bW=D[l@[$
Ű>v CYX}%T@|rHtz>RrN{R//+8do 96z6|-jo tIҨ%\'(~
Cv L
:u6%YAL YgV:5 MxsA(qW7<"*7^VC9ɨ'
qPvYHqȠThR 2cu?ZTxM i45QKZ-}ohv=o RD2{WFrӦ+h .tkk%eHyu&mu#L"d=l Je|?wөZr39^J80 $T./vaTK-%6el,;Ast4IwB>l*FbNn6+-ڲ\av^N
=!!W>7x) ̗ MzDt:?); ˈkC[M
8::ȓk=F!-7@ɗG3a~7vZKE&k1HLJ hI0 7Q;wy++>f?2o%^NEDУ-!Na6GĔ%ow0cØa?U;|җ*mɹaeVQ3-:%mC1m]ZwQ!:Wv@.ہauIv*S% )PDS' ;0h#d_^5*y 0O
KܪħT$+5_;L'1}je/an2j[JޗʹLM65 &oz
zڤFW P"Kwiթ *(LKK[uFw7܃ߣiL9R^Fn.] k*&<ہK)= "m MHhޕngye12v*A+CX 3g 4l=>^1{ۨNAVWyvG_Ni}k ^8 49J_c[ 1B ]bu0$;pZ0w20 9Yfҡ۠ 1d%/t6RNvcJ-îۤUo~}jL:V>l3GV4듆_xk6t=h
ڔ3 HwC",z L]\ o+ig?] XU`qz;sIQdAJVźJFa+kxxdùt-io_xGbmK\;i@ X±%FM?[FԻ \gB ҴΓ ! J:O VU*
tV褩3f?&$כJngǟKE?NR"KP=vC)Fܚ,(voo8Dsf{ӗV<k}jt((leG] ;δ]wr.q?TVx8ѪrC외}FY>FWz)|wpluH!D[-mHЕyG]Ք> L>!"\NuˏO?}d%xGh}ru=Kpn
M#q[T.V?m
(^]:BnQpP`7A6
y,_ uds}ktIW?N3g6vx
UJ2<)$q|MH n8RۑHa݀kOÃAo< -Kp;nf!zS~((lnp، >yPU+TI@86H=wƪ<
$ZnX
[X$jWRQU T +Ԯ)x7eʔ! ySRٳ=Lvꩧm(wuG qD={T.y̭m|JeG8֫ɕOۗuf[س|/KW`=ϷP<;Y1^PII,~h7;W.46RrVrnii63>z 5k' Jy9pU(
@ocnl>IT݆^Zx0 [' ߪ@
D-rRTMz!%ڎ?x$ͳԒɦncg$VjVIXC{V Fq4I'dG!`Aܪbڡ@I!ӧ sz?!ϊ(<~]u {;7^7L6
Y/3q,*؝Yvd
|TX| "熯Ď;8y,K9fj(](u~&JUR.'s7!+r=>t /qZW/8 &7K" xu-Wתw|H|:ÚMcBu nrTw2/<n[uM7DM$E)9X!W^
1y[CBur/%Ri';y'G ?G-]tEhumo q0r.h s-d=ʹ_%SEmS)͟/{9 Q #)ԓ%Zlemg67x"RƾQP_#ՠ#E~j\8#I .̸Q V }v[KO;x ৾Y6GqSdx1WatHe{=m,ՎWӎYʠ=Ur#;-5vѕ_
W%I4#]LǮ\P[UOD &W7ب^ ʭW_ "x1zѯΜۖݕrgke(ZUr "-6( oVPB
vز' Ua .2./QϺ^N,~r֓V#6C
t[m/Y;͑J뗘Ȓ%һ=@#C_O5O~iUJ*,1uNo\L?~&TEdb,35{s!ЯIhh SаWQ8E֠LqQ[vHQn ;,U dXn?|}GKYnq
w 3U(PQ`@<(XaGL~ٛtX}VJ;U+
T(=
tRy$>Gz#PɹIRu&?÷=W+
T(0l|-9菚!
*
tS P9ivɫNtO7vGgT*
TZ
tNyC}l*tƚ|qӰ>1 S!^Q@E@)OOH|'JRݑ ߮o+6)i
ႛ+>*}y7#p4̓1gi6NDLedhvx,6r0[B.܉.vmݘ[J<_ j҆ ݍ!,D}l?|,5uf} i5x(
HG#mL`rH_ܾTz8 a"h4(& ̝-
V1;5h1j4)|=T9uIOT].DQܮe9{^+'?ҠUr ;aعY[F|=iROMl ŪR/ z%,VQt7&02o*[ D]h ;4mRDUÄIHvryWz_E aNnF
ps;bhMbn
CkzṔ X z |At\5sLn䢤,v
70JѨ@FNS Ip"VK tK
f4뭸̊O- q]9e6P'8.U?>[AAӇ ~.nvY|(ϽJz70ʨ½lԧI>h:O?ê`-0uSJ7Mo~y8=~&labeO9xW x#3?g?'f,LOooy X$qAL ܡKzu>;bz;CIH eL;B^x *oi~8ӳqa0ę +}_^6C˅$)="*A2fR)+F.~} ^Ս,ʦ|\Z="V +EH/"%~Epk6XEgr=MUfV1SF|e [+ oJ5$\^sw7m׃-^XM#d`Nϟ^d13Ͷ呇Z3nk}6!+Cr5+>n
KJC* lٲzrA }>m6B/|20ғݣG
rMxڲj$L#h9
gJd- ],8j4x5 "AEI-<)EC@<&3|D%[˿OFL%hL)8.X*}JBM|c_\a%oBZAy¡^;kLj)1 hzj5|ˤ_spP'`( fVp zryh^)hxryzE˿m/,y!..!g! 7/b/3؈3&&8Y -`Fd&\a܃&I4/AbI}o # ZL]e u+vyIr5^nKHcu3ӫHW(eL ڇ rȈCH%Ɨ%'֧Dg?8` 噙 ɑٳg4 4'
nЙ>x ċ.p m["
yhW]u`Io.!LXssK c}Tٞ.#h`"+iϐ_p*Ve/Wllx[CIJG yg#êW$Y' ESGLb:>Lz)r)hҘ PzI'5p&x~ mg[1F( h$|Cr}x 7#3GK #
a&(cV XDZE"Ţ+o} [_E O?PR?V0i+Z 0(άXcݡ ]߃zﵜ{T M0fV&^dn0 GL+eyzk_b* "/O \IC~ 6b0-64@@SH_$"Y{^-{ [>KaA P5 آ%Ces^|>wbAв*D&%{B0jM:=>r
(斱В gZvkxYsiJ" ?Z[S ކa̠$u7c|`2&gv8W]o>sO Zi.gqhd c Zxr#Ish Ê({B.g'mK]ȝBj"5 KsxJIjf6ދke+/HZ
9I~ m3Thz%frQʃB)KTw*
e [1FB'wDI
:[")I R1x>A-({ErYXؘ"h
^##.*.Ё9Kg5XIXCN?;]~֫9L i;cP E')A' 1lZ/q M݈e6Z)
i Pb+l0)C{8s? _=w٠JJ`bM _|1 \ia-"BCJ, $/l1;z;y#" ɝ{arx ' %,F7t^^x!jCݱ ;f)e
J:`b``rGSg_njMHcQ 4k3P)TOƳ*+)hRLF d&fxB#w@Q,HyWa;5QϘ )=S/}Z cw [O͕}%)8J>.C٪:C)d%D!1Ic?1Q^m)e3CF7f<)|<%F aG*PҐ]CPTGjlΪXij,Bt96^ƍ"6 *%[L dll!BJE 5?R~\^!;p 1bpWyDMNo ZKjHf=`
gg[ D#*E |,Ij @i
c Ll[-#TDODN /D 1vo!_6I1-0OCԶֽ؉#\/S=@Y]v Qru"!jBҡ@ھlv+خ{шͽlGᬽo`k>MKF[KyV/Ba^)Y,#y|E*#(/GwI
bAA aůh4vFHbj6z9O*"2
(;.
ĺ8vr :Ě=$kZPIkȈTTIǣTv()]⏡Aߐjh($x)5O agK/8XP$BQ[vx4P`$EyN Qg`[ݱg%әRi) N0Y -0mQ2ʃ %`<3=끿 [fm `~ 6x~L?@R82Mɑ~~ k<m߱ښ/$
"8#]mz; -e99wZZ vxA0C q
[oMӧ;yGe&;As {a 4AEp |84Jy-!V@{^s~q 5T|L^W/>6Po{pMhWXQLh-| $ > $ޤ$2Y5:Q/.B:Fja!2`_C(Gi/ ͡ 8 gΆD{DŽPB*s84| Ev`2P2zC06mz*ue]!c$l( T+it_4M#x h,X7UHCD*
IѪ_p/:0- Ҿ /F|x1RF@E}bwH#(z+e.4Q xv6b6to~adiv
hBg{ Z/@d[6Rz#؎0b=8}z.]xyoU66YNlG/iސl)t
Nq<-MALJquM[ -/irj 9"xX a#6RTͮ m7
`ᤰ6|Y)Fza}z7.W[!r:2
ܗ)A+_N2M HUᤍm̜9S!2B
42Ztɶ"+q&*䑳O?IMyl<7V
Wg+k F($75 ŝO#%Zt|C@Ʀj@EF-lHpYT eg+w& IENDB` @ @ @ w& N o r m a l CJ _HaJ mH sH tH D A@ D D e f a u l t P a r a g r a p h F o n t R i R T a b l e N o r m a l 4
l 4 a ( k ( N o L i s t p ]@ p w& z - B o t t o m o f F o r m ! $d d $dN@oAa$ <CJ OJ QJ aJ R O R w& H e a d i n g -D $M
gd 5B*ph 4 @ 4 w& F o o t e r
! . )@ !.
g P a g e N u m b e r < +@ 2< n E n d n o t e T e x t CJ aJ > *@ A> n E n d n o t e R e f e r e n c e H* 4 R4 gG H e a d e r
! i B . # q$ & & & D' J) ) x* + c, , : 4 R q * I h k
D z : 5 w % ] / D & 3 ^ j k q
K
`
C D W g + H f y z & k " e D 0 G _ ` -! ! ! " Q" e" # $ $ s$ $ $ % L% u% & !& & & & & & G' H' ' ' &( j( k( ( ( ( M) P) ) ) ) /* {* |* * * * * + 2+ \+ + + f, i, , , /- e- - - - u. 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 N5 O5 o5 p5 q5 w8 y8 8 8 8 8 8 8 8 8 9 9 09 19 O9 P9 n9 o9 9 9 9 9 9 9 9 9 : : ': (: F: G: e: f: : : : : : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 @ 0 0 0 @ 0 0 0 @ 0 0 0 @ 0 0 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 0 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 @ 0 0 0 k " e & & & & & G' H' &( j( k( ( ( ( * * * + 2+ \+ - - - u. 2 2 2 2 2 2 2 N5 o5 : 00 00 00 @ 0 Z 00 Z 00 Z 00 @ 0 @ 0 @ 0 @ 0 Z 0 0 Z 0 0 Z 0 0 @ 0 @ 0 @ 0 Z 00 Z 00 Z 00 @ 0 @ 0 @ 0 j 00 gj 00 j 00 0
0 0 j 0 0 j 0 0 j 0 0 j 0 0 j 0 0
0 0E @ 0 @ 0
0 0 E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E E H & K j q i$ % B& C' ( * , 4- -. . / j0 0 ~1 1 2 "4 5 5 ; W>
C C " % & ( ) * , - . / 1 2 3 4 6 7 8 : ; < > ? @ A C D F G J K z & , . P1 4 ; yA C C # ' + 0 5 9 = B E H I C $ : QQ ' . 0 5 @ B H ! !! QQ 8 @ 0 (
B
S ? O L E _ L I N K 2 O L E _ L I N K 3 O L E _ L I N K 4 O L E _ L I N K 7 O L E _ L I N K 5 O L E _ L I N K 6 O L E _ L I N K 9 1 C D * : K
* c i * * : > > > |! > > L 2 2 3 : 2 3 3 : 9 *urn:schemas-microsoft-com:office:smarttagsplace = *urn:schemas-microsoft-com:office:smarttags PlaceType = *urn:schemas-microsoft-com:office:smarttags PlaceName 8 *urn:schemas-microsoft-com:office:smarttagsCity L " " " " # # 7$ 9$ -% 5% #& .& X& \& & & & & & & & & & & & ' 4' 8' =' ?' ' ' ' ' ) ) ) ) ) ) ) ) * .* g* k* + "+ , , 6, :, k, x, , , /- 5- e- k- 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 5 5 X8 \8 ]8 d8 : : ( * # # & & ' ' ' %( ) .* k, }, /- c- e- - 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 j8 p8 : : 3 3 3 3 3 3 3 3 3 3 / C D D % 3 3 " e 0 G & & M) ~) ) ) 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 N5 O5 O5 q5 5 5 S8 w8 w8 x8 y8 {8 {8 8 8 8 8 8 8 8 8 8 9 /9 19 n9 p9 9 9 9 9 9 9 : : ': (: F: G: e: f: : : : : 2 2 2 2 2 2 2 2 2 2 2 2 2 2 : }
u )b1 AG? gG =P gtQ n_]
` 3b 4Sp @t s, { w& E
g O $ 0 $c N b VC 3h n #4 E N . I n s t a n t F o r m a t 4L E N . L a y o u t ({L E N . L i b r a r i e s 5Lw < E N I n s t a n t F o r m a t > < E n a b l e d > 0 < / E n a b l e d > < S c a n U n f o r m a t t e d > 1 < / S c a n U n f o r m a t t e d > < S c a n C h a n g e s > 1 < / S c a n C h a n g e s > < / E N I n s t a n t F o r m a t > P< E N L a y o u t > < S t y l e > J A M A < / S t y l e > < L e f t D e l i m > { < / L e f t D e l i m > < R i g h t D e l i m > } < / R i g h t D e l i m > < F o n t N a m e > T i m e s N e w R o m a n < / F o n t N a m e > < F o n t S i z e > 1 2 < / F o n t S i z e > < R e f l i s t T i t l e > < / R e f l i s t T i t l e > < S t a r t i n g R e f n u m > 1 < / S t a r t i n g R e f n u m > < F i r s t L i n e I n d e n t > 0 < / F i r s t L i n e I n d e n t > < H a n g i n g I n d e n t > 7 2 0 < / H a n g i n g I n d e n t > < L i n e S p a c i n g > 0 < / L i n e S p a c i n g > < S p a c e A f t e r > 0 < / S p a c e A f t e r > < / E N L a y o u t > T < E N L i b r a r i e s > < L i b r a r i e s > < i t e m > a c c _ d o s i n g g u i d e s . e n l < / i t e m > < / L i b r a r i e s > < / E N L i b r a r i e s > @ kq ( * + : ` @ ` 2 ` h @ U n k n o w n G z T i m e s N e w R o m a n 5 S y m b o l 3& z A r i a l 7& V e r d a n a W T m s R m n T i m e s N e w R o m a n ; W i n g d i n g s B 1 h 9f9f + [ + [ ! 4 d 2 2 2q HX ? w& 2 C h u c k G r e e n f e l d
A d m i n i s t r a t o r Oh +'0 |
8 D
P \ d l t Chuck Greenfeld Normal.dot Administrator 2 Microsoft Office Word @ @ +@ + + ՜. +,0 h p
Columbia MedCom Group [ 2 ' Title
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z | } ~ R o o t E n t r y F 0YW3 D a t a
L ] 1 T a b l e { /9 W o r d D o c u m e n t ݗ S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8 C o m p O b j q
F Microsoft Office Word Document
MSWordDoc Word.Document.8 9q